Лиза Хендриксон-Джек - Пятый элемент здоровья. Как использовать менструальный цикл для поддержания жизненно важных функций организма

82. Shere, Mahvash, Priya Bapat, Cheri Nickel, Bhushan Kapur, and Gideon Koren. “Motherisk rounds: the effectiveness of folate-fortified oral contraceptives in maintaining optimal folate levels to protect against neural tube defects: a systematic review.” Journal of Obstetrics and Gynaecology Canada 37, no. 6 (2015): 527–533.

83. Leeton, John. “Depression induced by oral contraception and the role of vitamin B6 in its management.” Australian and New Zealand Journal of Psychiatry 8, no. 2 (1974): 85–88; Webb, J.L. “Nutritional effects of oral contraceptive use: a review.” The Journal of Reproductive Medicine 25, no. 4 (1980): 150–156; Rose, D.P., J.E. Leklem, R.R. Brown, and C. Potera. “Effect of oral contraceptives and vitamin B6 supplements on alanine and glycine metabolism.” The American Journal of Clinical Nutrition 29, no. 9 (1976): 956–960; Rios-Avila, Luisa, Bonnie Coats, Maria Ralat, Yueh-Yun Chi, Øivind Midttun, Per M. Ueland, Peter W. Stacpoole, and Jesse F. Gregory. “Pyridoxine supplementation does not alter in vivo kinetics of one-carbon metabolism but modifies patterns of one-carbon and tryptophan metabolites in vitamin B6– insufficient oral contraceptive users.” The American Journal of Clinical Nutrition 102, no. 3 (2015): 616–625.

84. Там же; Palmery, M., A. Saraceno, A. Vaiarelli, and G. Carlomagno. “Oral contraceptives and changes in nutritional requirements.” European Review for Medical and Pharmacological Sciences 17, no. 13 (2013): 1805–1808.

85. Akinloye, O., T.O. Adebayo, O.O. Oguntibeju, D.P. Oparinde, and E.O. Ogunyemi. “Effects of contraceptives on serum trace elements, calcium and phosphorus levels.” West Indian Medical Journal 60, no. 3 (2011): 308–315; Dante, Giulia, Alberto Vaiarelli, and Fabio Facchinetti. “Vitamin and mineral needs during the oral contraceptive therapy: a systematic review.” International Journal of Reproduction, Contraception, Obstetrics and Gynecology 3, no. 1 (2016): 1–10; Hess, Frances M., Janet C. King, and Sheldon Margen. “Zinc excretion in young women on low zinc intakes and oral contraceptive agents.” The Journal of Nutrition 107, no. 9 (1977): 1610–1620.

86. Palmery, M., A. Saraceno, A. Vaiarelli, and G. Carlomagno. “Oral contraceptives and changes in nutritional requirements.” European Review for Medical and Pharmacological Sciences 17, no. 13 (2013): 1808–1810; Webb, J.L. “Nutritional effects of oral contraceptive use: a review.” The Journal of Reproductive Medicine 25, no. 4 (1980): 150–156.

87. Akinloye, O., T.O. Adebayo, O.O. Oguntibeju, D.P. Oparinde, and E.O. Ogunyemi. “Effects of contraceptives on serum trace elements, calcium and phosphorus levels.” West Indian Medical Journal 60, no. 3 (2011): 310–315.

88. Hendrickson-Jack, Lisa. “FFP 203 | The Pill Problem | Ross Pelton.” Fertility Friday Podcast. Podcast Audio, June 1, 2018. fertilityfriday.com/203.

89. International Collaboration of Epidemiological Studies of Cervical Cancer. “Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies.” The Lancet 370, no. 9599 (2007): 1609–1621; Smith, Jennifer S., Jane Green, Amy Berrington De Gonzalez, Paul Appleby, Julian Peto, Martyn Plummer, Silvia Franceschi, and Valerie Beral. “Cervical cancer and use of hormonal contraceptives: a systematic review.” The Lancet 361, no. 9364 (2003): 1159–1167; Madeleine, Margaret M., Janet R. Daling, Stephen M. Schwartz, Katherine Shera, Barbara McKnight, Joseph J. Carter, Gregory C. Wipf. “Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix.” Cancer Epidemiology and Prevention Biomarkers 10, no. 3 (2001): 171–177.

90. Hendrickson-Jack, Lisa. “FFP 095 | Cervical Cancer & The Pill | Menstrual Suppression | Cervical Dysplasia | Abnormal Pap | No More Periods? The Blessings of the Curse | Dr. Susan Rako.” Fertility Friday Podcast. Podcast Audio, September 9, 2016. fertilityfriday.com/95.

91. Braaten, Kari P., and Marc R. Laufer. “Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine.” Reviews in Obstetrics and Gynecology 1, no. 1 (2008): 2–10; Centers for Disease Control and Prevention. Genital HPV Infection Fact Sheet. (2004). Rockville, MD: CDC National Prevention Information Network.

92. Marks, Morgan, Patti E. Gravitt, Swati B. Gupta, Kai-Li Liaw, Amha Tadesse, Esther Kim, Chailert Phongnarisorn et al. “Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand.” Journal of Infectious Diseases (2011): 1509.

93. Beral, Valerie, Carol Hermon, Clifford Kay, Philip Hannaford, Sarah Darby, and Gillian Reeves. “Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners’ oral contraception study.” The BMJ 318, no. 7176 (1999): 96–100.

94. Piyathilake, Chandrika J., Olga L. Henao, Maurizio Macaluso, Phillip E. Cornwell, Sreelatha Meleth, Douglas C. Heimburger, and Edward E. Partridge. “Folate is associated with the natural history of high-risk human papillomaviruses.” Cancer Research 64, no. 23 (2004): 8788–8793; Piyathilake, Chandrika J., Maurizio Macaluso, Ilene Brill, Douglas C. Heimburger, and Edward E. Partridge. “Lower red blood cell folate enhances the HPV-16–associated risk of cervical intraepithelial neoplasia.” Nutrition 23, no. 3 (2007): 203–210; Zhao, W., M. Hao, Y. Wang, N. Feng, Z. Wang, W. Wang, J. Wang, and L. Ding. “Association between folate status and cervical intraepithelial neoplasia.” European Journal of Clinical Nutrition (2016); Jia, W.L., L. Ding, Z.Y. Ren, T.T. Wu, W.M. Zhao, S.L. Fan, and J.T. Wang. “Effects of both folic acid, p16 protein expression and their interaction on progression of cervical cancerization.” Chinese Journal of Epidemiology 37, no. 12 (2016): 1647–1652; Hao, Min, Weihong Zhao, Lili Zhang, Honghong Wang, and Xin Yang. “Low folate levels are associated with methylation-mediated transcriptional repression of miR-203 and miR-375 during cervical carcinogenesis.” Oncology Letters 11, no. 6 (2016): 3863–3869; Li, Q.L., L. Ding, J. Nan, C.L. Liu, Z.K. Yang, F. Chen, Y.L. Liang, and J.T. Wang. “Relationship and interaction between folate and expression of methyl-CpG-binding protein 2 in cervical cancerization.” Chinese Journal of Epidemiology 37, no. 7 (2016): 985–991; Bai, Li-Xia, Jin-Tao Wang, Ling Ding, Shi-Wen Jiang, Hui-Jie Kang, Chen-Fei Gao, Xiao Chen, Chen Chen, and Qin Zhou. “Folate deficiency and FHIT hypermethylation and HPV 16 infection promote cervical cancerization.” Asian Pacific Journal of Cancer Prevention 15, no. 21 (2014): 9313–9317.

95. Iversen, Lisa, Selvaraj Sivasubramaniam, Amanda J. Lee, Shona Fielding, and Philip C. Hannaford. “Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study.” American Journal of Obstetrics and Gynecology 216, no. 6 (2017): 580-e1; Cogliano, Vincent, Yann Grosse, Robert Baan, Kurt Straif, Béatrice Secretan, and Fatiha El Ghissassi. “Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment.” The Lancet Oncology 6, no. 8 (2005): 552–553; Urban, Margaret, Emily Banks, Sam Egger, Karen Canfell, Dianne O’Connell, Valerie Beral, and Freddy Sitas. “Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case – control study.” PLOS Medicine 9, no. 3 (2012): e1001182: 1–11; Forman, D., T.J. Vincent, and R. Doll. “Cancer of the liver and the use of oral contraceptives.” The BMJ (Clinical Research Edition) 292, no. 6532 (1986): 1357–1361; Henderson, B.E., S. Preston-Martin, H.A. Edmondson, R.L. Peters, and M.C. Pike. “Hepatocellular carcinoma and oral contraceptives.” British Journal of Cancer 48, no. 3 (1983): 437; Bassuk, Shari S., and JoAnn E. Manson. “Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes.” Annals of Epidemiology 25, no. 3 (2015): 193–200.

96. Gierisch, Jennifer M., Remy R. Coeytaux, Rachel Peragallo Urrutia, Laura J. Havrilesky, Patricia G. Moorman, William J. Lowery, Michaela Dinan et al. “Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.” Cancer Epidemiology and Prevention Biomarkers (2013): 1931–1943; Bassuk, Shari S., and JoAnn E. Manson. “Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes.” Annals of Epidemiology 25, no. 3 (2015): 193–200; Fernandez, E., C. La Vecchia, A. Balducci, L. Chatenoud, S. Franceschi, and E. Negri. “Oral contraceptives and colorectal cancer risk: a meta-analysis.” British Journal of Cancer 84, no. 5 (2001): 722–727; Bosetti, Cristina, Francesca Bravi, Eva Negri, and Carlo La Vecchia. “Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis.” Human Reproduction Update 15, no. 5 (2009): 489–498.

97. Urban, Margaret, Emily Banks, Sam Egger, Karen Canfell, Dianne O’Connell, Valerie Beral, and Freddy Sitas. “Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study.” PLOS Medicine 9, no. 3 (2012): 9; Iversen, Lisa, Selvaraj Sivasubramaniam, Amanda J. Lee, Shona Fielding, and Philip C. Hannaford. “Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study.” American Journal of Obstetrics and Gynecology (2017); Grevers, Xin, Anne Grundy, Abbey E. Poirier, Farah Khandwala, Matthew Feldman, Christine M. Friedenreich, and Darren R. Brenner. “Cancer incidence attributable to the use of oral contraceptives and hormone therapy in Alberta in 2012.” CMAJ Open 4, no. 4 (2016): E757–E759.

98. Cogliano, Vincent, Yann Grosse, Robert Baan, Kurt Straif, Béatrice Secretan, and Fatiha El Ghissassi. “Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment.” The Lancet Oncology 6, no. 8 (2005): 553.

99. Franceschi, Silvia. (2005) “The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.” Tumor Prevention and Genetics III. Springer Berlin Heidelberg, 277–297.

100. Там же.

101. Там же, 283.

102. Beral, Valerie, Carol Hermon, Clifford Kay, Philip Hannaford, Sarah Darby, and Gillian Reeves. “Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners’ oral contraception study.” The BMJ 318, no. 7176 (1999): 99.

103. Maletzky, Barry M., Arthur Tolan, and Bentson McFarland. “The Oregon depo-provera program: a five-year follow-up.” Sexual Abuse: A Journal of Research and Treatment 18, no. 3 (2006): 303–316; Prentky, Robert A. “Arousal reduction in sexual offenders: A review of antiandrogen interventions.” Sexual Abuse: A Journal of Research and Treatment 9, no. 4 (1997): 335–347; Lee, Joo Yong, and Kang Su Cho. “Chemical castration for sexual offenders: physicians’ views.” Journal of Korean Medical Science 28, no. 2 (2013): 171–17; Scott, Charles L., and Trent Holmberg. “Castration of sex offenders: prisoners’ rights versus public safety.” Journal of the American Academy of Psychiatry and the Law 31 (2003): 502–509.

1. Nilsson, Carl Gustaf, Pekka Lähteenmäki, and Tapani Luukkainen. “Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.” Contraception 21, no. 3 (1980): 225–233; Xiao, Bilian, Tao Zeng, Shangchun Wu, Hongzhu Sun, and Na Xiao. “Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.” Contraception 51, no. 6 (1995): 359–365; Jeppsson, S., and E.D.B. Johansson. “Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of Depo-Provera to women.” Contraception 14, no. 4 (1976): 461–469; Duijkers, Ingrid J.M., Doris Heger-Mahn, Dominique Drouin, and Sven Skouby. “A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen.” The European Journal of Contraception & Reproductive Health Care 20, no. 6 (2015): 419–427; Lakha, F., P.C. Ho, Z.M. Van der Spuy, K. Dada, R. Elton, A.F. Glasier, H.O.D. Critchley, A.R.W. Williams, and D.T. Baird. “A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel).” Human Reproduction 22, no. 9 (2007): 2428–2436.